Please login to the form below

Not currently logged in
Email:
Password:

Patent loss

This page shows the latest Patent loss news and features for those working in and with pharma, biotech and healthcare.

UK Supreme Court rules in favour of Servier in NHS patent lawsuit

UK Supreme Court rules in favour of Servier in NHS patent lawsuit

The UK Supreme Court has unanimously ruled in favour of French pharma company Servier over a decade-long patent case filed by the NHS regarding the hypertension drug Coversyl. ... prices. Although the patent on Coversyl expired in 2001, the first generic

Latest news

More from news
Approximately 1 fully matching, plus 154 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Pfizer is coming off ten years of patent expiries, plus a pipeline that hasn’t yielded as many new products as hoped in that period, and that prompted Bourla to implement ... He has already taken some pretty seismic decisions, such as axing R&D in

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    There’s also some urgency for the transaction to go quickly and smoothly as AbbVie prepares for the loss of patent protection for $20bn immunology drug Humira (adalimumab) in the US ... AZ’s new growth phase comes after a six-year sales slump thanks

  • Deal Watch October 2018

    The termination comes as a consequence of patent infringement litigation which has placed a stay on the FDA’s approval of the biosimilar, Lusduna Nexvue, in the US. ... non‐biologic product post‐patent loss, highlighting the benefits of biologics

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    years for AZ to return to top-line growth after the patent loss of blockbuster brands such as Nexium and Crestor.

  • Pharma deals during February 2014 Pharma deals during February 2014

    given the loss of patent protection on Forest's best selling depression drug Lexapro and another patent cliff looming for Nameda, its Alzheimer's drug in 2015.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins Insights

Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....